Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

VEGF as a Prognostic Factor for White Matter Damage in Preterm Infants

This study has been withdrawn prior to enrollment.
Information provided by:
Hadassah Medical Organization Identifier:
First received: November 25, 2007
Last updated: September 1, 2016
Last verified: November 2007
We hypothesize that misexpression of vascular endothelial growth factor (VEGF) in the Cerebrospinal fluid of preterm infants can be used as a biomarker to predict the risk for developing white matter damage.

Preterm Infants With White Matter Damage
Preterm Infants Developing Normally

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: VEGF as a Prognostic Factor for White Matter Damage in Preterm Infants

Further study details as provided by Hadassah Medical Organization:

Biospecimen Retention:   Samples Without DNA

Enrollment: 0
Study Start Date: January 2008
Estimated Study Completion Date: January 2009


Ages Eligible for Study:   25 Weeks to 40 Weeks   (Child)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
preterm infants.

Inclusion Criteria:

  • Preterm infants undergoing lumbar puncture.

Exclusion Criteria:

  • Preterm with IVH or known infection or meningitis.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00564161

Sponsors and Collaborators
Hadassah Medical Organization
Principal Investigator: Talya Dor, MD Hadassah Medical Organization
  More Information Identifier: NCT00564161     History of Changes
Other Study ID Numbers: 606060-HMO-CTIL 
Study First Received: November 25, 2007
Last Updated: September 1, 2016
Health Authority: Israel: Israeli Health Ministry Pharmaceutical Administration

Additional relevant MeSH terms:
Premature Birth
Obstetric Labor, Premature
Obstetric Labor Complications
Pregnancy Complications processed this record on October 27, 2016